Reuters Highlights AOA Dx Blood Test's 92% Accuracy in Ovarian Cancer Detection
Our portfolio company AOA Dx has achieved a significant milestone in ovarian cancer diagnostics with the validation of its multi-omic, AI-powered blood test. A recent peer-reviewed study highlighted by Nancy Lapid for Thomson Reuters demonstrated 92% accuracy across all ovarian cancer stages and 88% accuracy for early-stage (Stage I–II) disease.
Ovarian cancer remains the fifth leading cause of cancer-related deaths among women, mainly due to late diagnosis. AOA Dx's approach provides a faster and more reliable diagnostic pathway during the critical window when intervention can make the greatest difference.
We're proud to support CEO Oriana Papin-Zoghbi and the AOA Dx team as they advance precision diagnostics in oncology.